Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report)'s share price traded down 3.2% during trading on Wednesday . The stock traded as low as $12.53 and last traded at $12.26. 4,275 shares were traded during mid-day trading, a decline of 99% from the average session volume of 465,490 shares. The stock had previously closed at $12.66.
Wall Street Analysts Forecast Growth
A number of research firms have recently commented on BCAX. Wedbush restated an "outperform" rating and issued a $31.00 price objective on shares of Bicara Therapeutics in a research report on Thursday, March 27th. HC Wainwright reduced their price objective on shares of Bicara Therapeutics from $45.00 to $44.00 and set a "buy" rating on the stock in a report on Monday. Stifel Nicolaus set a $48.00 price objective on Bicara Therapeutics in a research note on Thursday, March 27th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $13.01 target price on shares of Bicara Therapeutics in a report on Thursday, March 13th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $36.50.
Check Out Our Latest Report on Bicara Therapeutics
Bicara Therapeutics Stock Performance
The firm's 50-day moving average is $13.07 and its 200 day moving average is $17.46.
Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last released its quarterly earnings results on Thursday, March 27th. The company reported ($0.39) earnings per share for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.08). Equities research analysts expect that Bicara Therapeutics Inc. will post -2.59 EPS for the current fiscal year.
Institutional Trading of Bicara Therapeutics
Several hedge funds have recently added to or reduced their stakes in BCAX. California State Teachers Retirement System acquired a new position in shares of Bicara Therapeutics in the 4th quarter worth $25,000. Spire Wealth Management bought a new stake in shares of Bicara Therapeutics in the fourth quarter valued at approximately $31,000. BNP Paribas Financial Markets acquired a new stake in shares of Bicara Therapeutics during the 4th quarter worth approximately $32,000. Legal & General Group Plc acquired a new position in Bicara Therapeutics in the fourth quarter worth about $33,000. Finally, Summit Investment Advisors Inc. acquired a new stake in shares of Bicara Therapeutics in the 4th quarter valued at $35,000.
Bicara Therapeutics Company Profile
(
Get Free Report)
Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
Featured Stories
Before you consider Bicara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicara Therapeutics wasn't on the list.
While Bicara Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
